|
Orthologous residues
|
|
H2AX (human): S140‑p, H2AX (mouse): S140‑p, H2AX (rat): S140‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site
|
|
Disease tissue studied:
bone cancer
|
|
Relevant cell lines - cell types - tissues:
MEF (fibroblast), U2OS (bone cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Comments:
MEFs were H2AX -/- p53 -/-
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
ionizing radiation
|
|
|
|
increase
|
|
|
siRNA
|
ionizing radiation
|
|
|
inhibit treatment-induced increase
|
MDC1 shRNA. Increases kinetics of dephosphorylation.
|
|
|
ionizing radiation
|
|
|
inhibit treatment-induced increase
|
ATM/DNA-PKcs inhibitors
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization, molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
PARP1 (human)
|
|
Induces
|
|
|
pull-down assay
|
|
MDC1 (human)
|
BRCT
|
Induces
|
|
|
pull-down assay
|
|
NBS1 (human)
|
|
Induces
|
|
|
pull-down assay
|
|
Rad50 (human)
|
|
Induces
|
|
|
pull-down assay
|
|
|
Comments:
T136A,S139A did not localize to MDC1 IRIF nuclear foci and did not complement the null.
|